Hepatic stellate cells as a target for the treatment of liver fibrosis

Seminars in Liver Disease

Volumn 21, Issue 3, 2001, Pages 437-451

  Bataller, R ^a   Brenner, D A ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Antifibrotic therapy; Collagen synthesis; Hepatic stellate cells

Indexed keywords

ALPHA INTERFERON; AMILORIDE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIFIBROTIC AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; ANTIVIRUS AGENT; COLCHICINE; CORTICOSTEROID; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR ANTAGONIST; FUMAGILLOL CHLOROACETYLCARBAMATE; GAMMA INTERFERON; GLYCYRRHIZIC ACID; HALOFUGINONE; HERBACEOUS AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; LUFIRONIL; MALOTILATE; PENTOXIFYLLINE; PHOSPHATIDYLCHOLINE; RECOMBINANT INTERLEUKIN 10; RIBAVIRIN; SATURATED FATTY ACID; SCATTER FACTOR; SILYMARIN; TOCOPHEROL; UNINDEXED DRUG; XIAO CHAI HU TANG;

ADULT; ANIMAL MODEL; AUTOIMMUNE HEPATITIS; CLINICAL TRIAL; COLLAGEN SYNTHESIS; DRUG INDUCED DISEASE; EXPERIMENTAL MODEL; EXTRACELLULAR MATRIX; FIBROGENESIS; HEPATITIS C; HUMAN; INFLAMMATION; LIVER CELL; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; MOUSE; MULTICENTER STUDY; NONHUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; SCAR FORMATION; STELLATE CELL;

CHRONIC DISEASE; COLLAGEN; CYTOKINES; HUMANS; INFLAMMATION; LIVER; LIVER CIRRHOSIS;

EID: 0034809804     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-17558     Document Type: Review

References (177)

1. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury
2. Liver fibrosis
3. Fibrogenesis I. New insights into hepatic stellate cell activation: The simple becomes complex
4. Hepatic stellate cells: A target for the treatment of liver fibrosis
5. Collagen measured in primary, cultures of normal rat hepatocytes derives from lipocytes within the monolayer
6. Hepatic lipocytes: The principal collagen-producing cells of normal rat liver
7. Stimulation of hepatic lipocyte collagen production by Kupffer cell-derived transforming growth factor beta: Implication for a pathogenetic role in alcoholic liver fibrogenesis
8. Cellular localization of type I III and IV procollagen gene transcripts in normal and fibrotic human liver
9. Acetaldehyde-induced stimulation of collagen synthesis and gene expression is dependent on conditions of cell culture: Studies with rat lipocytes and fibroblasts
10. Posttranscriptional regulation of collagen alpha1(I) mRNA in hepatic stellate cells
11. Cellular sources of extracellular matrix proteins in normal and fibrotic liver. Studies of gene expression by in situ hybridization
12. Correlation between Ito cells and fibrogenesis in an experimental model of hepatic fibrosis. A sequential stereological study
13. Localization of liver myofibroblasts and hepatic stellate cells in normal and diseased rat livers: Distinct roles of (myo-)fibroblast subpopulations in hepatic tissue repair
14. Interferon gamma decreases hepatic stellate cell activation and extracellular matrix deposition in rat liver fibrosis
15. Halofuginone to prevent and treat thioacetamide-induced liver fibrosis in rats
16. Prevention and treatment of liver fibrosis based on pathogenesis
17. Rat liver myofibroblasts and hepatic stellate cells: Different cell populations of the fibroblast lineage with fibrogenic potential
18. Activation-dependent contractility of rat hepatic lipocytes in culture and in vivo
19. Perisinusoidal stellate cells of the liver: Important roles in retinol metabolism and fibrosis
20. Activation of cultured rat hepatic lipocytes by Kupffer cell conditioned medium. Direct enhancement of matrix synthesis and stimulation of cell proliferation via induction of platelet-derived growth factor receptors
21. Leukocytes as modulators of stellate cell activation
22. Molecular dissection of the mitogenic effect of hepatocytes on cultured hepatic stellate cells
23. Pathogenesis of liver fibrosis: Role of oxidative stress
24. Intracellular signaling pathways in stellate cell activation
25. Effect of antioxidants, resveratrol, quercetin, and N-acetylcysteine, on the functions of cultured rat hepatic stellate cells and Kupffer cells
26. Transforming growth factor-beta1 induces activation of Ras, Raf-1, MEK and MAPK in rat hepatic stellate cells
27. Effects of platelet-derived growth factor and other polypeptide mitogens on DNA synthesis and growth of cultured rat liver fat-storing cells
28. Cellular localization of endothelin-1 and increased production in liver injury in the rat: Potential for autocrine and paracrine effects on stellate cells
29. Extracellular signal-regulated kinase activation differentially regulates platelet-derived growth factor's actions in hepatic stellate cells, and is induced by in vivo liver injury in the rat
30. Modulation of transforming growth factor beta receptors of rat lipocytes during the hepatic wound healing response. Enhanced binding and reduced gene expression accompany cellular activation in culture and in vivo
31. Appearance of alpha-smooth-muscle-actin-positive cells in hepatic fibrosis
32. Modulation of alpha smooth muscle actin and desmin expression in perisinusoidal cells of normal and diseased human livers
33. Signal transduction in hepatic stellate cells
34. Expression of platelet-derived growth factor in a model of acute liver injury
35. Expression of platelet-derived growth factor and its receptors in normal human liver and during active hepatic fibrogenesis
36. Thrombin stimulates proliferation of liver fat-storing cells and expression of monocyte chemotactic protein-1: Potential role in liver injury
37. Arginine vasopressin induces contraction and stimulates growth of cultured human hepatic stellate cells
38. Angiotensin II induces contraction and proliferation of human hepatic stellate cells
39. Growth inhibitory properties of endothelin-1 in human hepatic myofibroblastic Ito cells. An endothelin B receptor-mediated pathway
40. Role of NF-kappaB in the antiproliferative effect of endothelin-1 and tumor necrosis factor-alpha in human hepatic stellate cells. Involvement of cyclooxygenase-2
41. Antiproliferative properties of sphingosine 1-phosphate in human hepatic myofibroblasts. A cyclooxygenase-2 mediated pathway
42. Involvement of reactive oxygen species and nitric oxide radicals in activation and proliferation of rat hepatic stellate cells
43. Nitrovasodilators inhibit platelet-derived growth factor-induced proliferation and migration of activated human hepatic stellate cells
44. The mitogenic effect of platelet-derived growth factor in human hepatic stellate cells requires calcium influx
45. + exchange activation by platelet-derived growth factor in rat hepatic stellate cells
46. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors
47. Apoptosis of hepatic stellate cells: Involvement in resolution of biliary fibrosis and regulation by soluble growth factors
48. The up-and-down of hepatic stellate cells in tissue injury: Apoptosis restores cellular homeostasis
49. Phosphatidylinositol-3 kinase and extracellular signal-regulated kinase mediate the chemotactic and mitogenic effects of insulin-like growth factor-I in human hepatic stellate cells
50. In vitro migratory potential of rat quiescent hepatic stellate cells and its augmentation by cell activation
51. Monocyte chemotactic protein-1 as a chemoattractant for human hepatic stellate cells
52. Liver fibrosis and altered matrix synthesis
53. Expression and matrix deposition of latent transforming growth factor beta binding proteins in normal and fibrotic rat liver and transdifferentiating hepatic stellate cells in culture
54. Transforming growth factor-beta initiates wound repair in rat liver through induction of the EIIIA-fibronectin splice isoform
55. Discoidin domain receptor 2 (DDR2) interacts with SRC and SHC following activation by collagen I
56. Interplay of matrix and myofibroblasts during hepatic fibrogenesis
57. Expression and function of integrin receptors for collagen and laminin in cultured human hepatic stellate cells
58. Induction of cellular processes containing collagenase and retinoid by integrin-binding to interstitial collagen in hepatic stellate cell culture
59. Molecular signalling mechanisms controlling growth and function of cardiac fibroblasts
60. Inhibition of experimentally induced liver cirrhosis in rats by a nonpeptidic mimetic of the extracellular matrix-associated Arg-Gly-Asp epitope
61. Hepatic stellate cells and the regulation of liver inflammation
62. Cytokines and fibrogenesis
63. Inhibition of NFκB in activated rat hepatic stellate cells by proteosome inhibitors and an IκB super-repressor
64. Signal transduction by the chemokine receptor cxcr3. Activation of ras/erk, src, and phosphatidylinositol 3-kinase/akt controls cell migration and proliferation in human vascular pericytes
65. Activated human stellate cells express the cell machinery required for antigen presentation and modulate the proliferation of allogenic lymphocytes
66. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: A pilot trial of interferon nonresponders
67. Fibrogenesis. III. Posttranscriptional regulation of type I collagen
68. The 5′ stem-loop regulates expression of collagen alpha1(I) mRNA in mouse fibroblasts cultured in a three-dimensional matrix
69. Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis
70. Progelatinase A is produced and activated by rat hepatic stellate cells and promotes their proliferation
71. Expression patterns of matrix metalloproteinases and their inhibitors in parenchymal and non-parenchymal cells of rat liver: Regulation by TNF-alpha and TGF-beta1
72. Expression of matrix metalloproteinases and their inhibitors during hepatic tissue repair in the rat
73. Tissue inhibitor of metalloproteinases-1 promotes liver fibrosis development in a transgenic mouse model
74. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy
75. Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct
76. Histological course of alcoholic hepatitis. Influence of abstinence, sex and extent of hepatic damage
77. Hepatic stellate cell activation in genetic haemochromatosis. Lobular distribution, effect of increasing hepatic iron and response to phlebotomy
78. Prognosis of wilsonian chronic active hepatitis
79. 2 and cyclooxygenase-2
80. Molecular and cellular aspects of iron-induced hepatic cirrhosis in rodents
81. Bile acid stimulation of early growth response gene and mitogen-activated protein kinase is protein kinase C-dependent
82. Fibrosis in patients with chronic hepatitis C: Detection and significance
83. Natural history of liver fibrosis progression in patients with chronic hepatitis C
84. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C
85. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
86. Effects of interferon therapy in "non responder" patients with chronic hepatitis C
87. Long-term administration of interferon-alpha in non-responder patients with chronic hepatitis C: Follow-up of liver fibrosis over 5 years
88. Interferon alfa and gamma inhibit proliferation and collagen synthesis of human Ito cells in culture
89. Cholestasis-induced fibrosis is reduced by interferon alpha-2a and is associated with elevated liver metalloprotease activity
90. Molecular pathogenesis of liver disease: An approach to hepatic inflammation, cirrhosis and liver transplant tolerance
91. Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone
92. Colchicine for alcoholic and nonalcoholic liver fibrosis and cirrhosis
93. Neutrophil-derived superoxide anion induces lipid peroxidation and stimulates collagen synthesis in human hepatic stellate cells: Role of nitric oxide
94. Reversibility of hepatic fibrosis in autoimmune hepatitis
95. Alcoholic hepatitis superimposed on cirrhosis. Clinical significance and effect of long-term prednisone treatment
96. A controlled trial of prednisolone treatment in primary biliary cirrhosis. Three-year results
97. The combination of prednisone and colchicine in patients with primary sclerosing cholangitis
98. Colchicine in the treatment of cirrhosis of the liver
99. A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis
100. The effect of malotilate on type III and type IV collagen, laminin and fibronectin metabolism in dimethylnitrosamine-induced liver fibrosis in the rat
101. The prognosis of patients with alcoholic liver disease. An international randomized, placebo-controlled trial on the effect of malotilate on survival
102. An interleukin-1 receptor antagonist decreases fibrosis induced by dimethylnitrosamine in rat liver
103. The use of synthetic analogues of Arg-Gly-Asp (RGD) and soluble receptor of tumor necrosis factor to prevent acute and chronic experimental liver injury
104. Interleukin-10 controls neutrophilic infiltration, hepatocyte proliferation, and liver fibrosis induced by carbon tetrachloride in mice
105. NADPH oxidase-derived free radicals are key oxidants in alcohol-induced liver disease
106. Attenuation of alcohol-induced apoptosis of hepatocytes in rat livers by polyenylphosphatidylcholine (PPC)
107. Alcoholic liver disease: New insights in pathogenesis lead to new treatments
108. S-adenosylmethionine prevents hepatic tocopherol depletion in carbon tetrachloride-injured rats
109. Antioxidant defenses in metal-induced liver damage
110. Vitamin E dietary supplementation protects against carbon tetrachloride-induced chronic liver damage and cirrhosis
111. Effects of long-term vitamin E supplementation in alcoholic cirrhotics
112. Silymarin retards collagen accumulation in early and advanced billary fibrosis secondary to complete bile duct obliteration in rats
113. Effects of silymarin in alcoholic patients with cirrhosis of the liver: Results of a controlled, double-blind, randomized and multicenter trial
114. Polyenylphosphatidylcholine attenuates non-alcoholic hepatic fibrosis and accelerates its regression
115. Polyenylphosphatidylcholine prevents carbon tetrachloride-induced lipid peroxidation while it attenuates liver fibrosis
116. Dilinoleoylphosphatidylcholine decreases hepatic stellate cell activation
117. Role of S-adenosyl-L-methionine in the treatment of liver diseases
118. Effect of nifedipine and S-adenosylmethionine in the liver of rats treated with CCl4 and ethanol for one month
119. Effects of S-adenosyl-L-methionine and interferon-alpha2b on liver damage induced by bile duct ligation in rats
120. S-adenosyl-methionine in alcoholic liver cirrhosis: A randomized, placebo-controlled, double-blind, multicenter clinical trial
121. Retinyl palmitate reduces hepatic fibrosis in rats induced by dimethylnitrosamine or pig serum
122. Deactivation of cultured human liver myofibroblasts by trans-resveratrol, a grapevine-derived polyphenol
123. The role of growth factors, cytokines, and vasoactive compounds in obstructive nephropathy
124. Fibrogenesis. V. TGF-beta signaling pathways
125. Protease inhibitors suppress TGF-beta generation by hepatic stellate cells
126. Inhibition of transforming growth factor beta prevents progression of liver fibrosis and enhances hepatocyte regeneration in dimethylnitrosamine-treated rats
127. In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: A potential new therapy for hepatic fibrosis
128. Blockade of type beta transforming growth factor signaling prevents liver fibrosis and dysfunction in the rat
129. Activated rat stellate cells express c-met and respond to hepatocyte growth factor to enhance transforming growth factor beta1 expression and DNA synthesis
130. Hepatocyte growth factor gene therapy of liver cirrhosis in rats
131. Inhibition of rat hepatic lipocyte activation in culture by interferon-gamma
132. Interferon gamma decreases hepatic stellate cell activation and extracellular matrix deposition in rat liver fibrosis
133. Strain-specific differences in mouse hepatic wound healing are mediated by divergent T helper cytokine responses
134. Pentoxifylline inhibits growth and collagen synthesis of cultured human hepatic myofibroblast-like cells
135. Inhibition by pentoxifylline of extracellular signal-regulated kinase activation by platelet-derived growth factor in hepatic stellate cells
136. Pharmacological aspects of pentoxifylline with emphasis on its inhibitory actions on hepatic fibrogenesis
137. + exchanger modulates the fibrogenic effect of oxidative stress in rat hepatic stellate cells
138. Inhibition of the Na(+)/H(+) exchanger reduces rat hepatic stellate cell activity and liver fibrosis: An in vitro and in vivo study
139. The Ras antagonist, farnesylthiosalicylic acid (FTS), inhibits experimentally-induced liver cirrhosis in rats
140. Peroxisome proliferator-activated receptors and hepatic stellate cell activation
141. Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells
142. A histone deacetylase inhibitor, trichostatin A, suppresses myofibroblasfic differentiation of rat hepatic stellate cells in primary culture
143. Inhibition of hepatic stellate cell proliferation and activation by the semisynthetic analogue of fumagillin TNP-470 in rats
144. The role of vasoactive compounds, growth factors and cytokines in the progression of renal disease
145. Mechanism of cardiac fibrosis by angiotensin. New insight revealed by genetic engineering
146. Angiotensin converting enzyme inhibition attenuates the development of hepatic fibrosis in the rat bile duct ligation model
147. Vasoactive agents in intrahepatic portal hypertension and fibrogenesis: Implications for therapy
148. Endothelin 1 is overexpressed in human cirrhotic liver and exerts multiple effects on activated hepatic stellate cells
149. An oral endothelin-A receptor antagonist blocks collagen synthesis and deposition in advanced rat liver fibrosis
150. 2 in thioacetamide-induced liver cirrhosis
151. Increased activity of nuclear factor-kappaB participates in cardiovascular remodeling induced by chronic inhibition of nitric oxide synthesis in rats
152. Role of monocyte chemoattractant protein-1 in cardiovascular remodeling induced by chronic blockade of nitric oxide synthesis
153. Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: Endothelial dysfunction in portal hypertension
154. Role of prostanoids and nitric oxide inhibition in rats with experimental hepatic fibrosis
155. Antifibrotic and hemodynamic effects of the early and chronic administration of octreotide in two models of liver fibrosis in rats
156. Octreotide decreases connective tissue formation and improves vascular changes associated with hepatic schistosomiasis
157. 4-induced cirrhosis: Protective role of adenosine administration
158. Steatosis and collagen content in experimental liver cirrhosis are affected by dietary monounsaturated and polyunsaturated fatty acids
159. Influence of administration of long-chain polyunsaturated fatty acids on process of histological recovery in liver cirrhosis produced by oral intake of thioacetamide
160. Dietary saturated fatty acids down-regulate cyclooxygenase-2 and tumor necrosis factor alfa and reverse fibrosis in alcohol-induced liver disease in the rat
161. Influence of dietary zinc on hepatic collagen and prolyl hydroxylase activity in alcoholic rats
162. Fibrogenic and collagenolytic activity in carbon-tetrachloride-injured rats: Beneficial effects of zinc administration
163. Effects of Shosaiko-to, a Japanese herbal medicine, on hepatic fibrosis in rats
164. Effects of sho-saiko-to extract on fibrosis and regeneration of the liver in rats
165. Antifibrotic effects of a polysaccharide extracted from Ganoderma lucidum, glycyrrhizin, and pentoxifylline in rats with cirrhosis induced by biliary obstruction
166. Anti-fibrotic effects of a hot-water extract from Salvia miltiorrhiza roots on liver fibrosis induced by biliary obstruction in rats
167. Prolyl 4-hydroxylase inhibitor (HOE 077) prevents TIMP-1 gene expression in rat liver fibrosis
168. Two novel antifibrotics, HOE 077 and Safironil, modulate stellate cell activation in rat liver injury: Differential effects in males and females
169. The prolyl 4-hydroxylase inhibitor HOE 077 prevents activation of Ito cells, reducing procollagen gene expression in rat liver fibrosis induced by choline-deficient L-amino acid-defined diet
170. Prolyl 4-hydroxlase inhibitor (HOE 077) inhibits pig serum-induced rat liver fibrosis by preventing stellate cell activation
171. Selective inhibition of hepatic collagen accumulation in experimental liver fibrosis in rats by a new prolyl 4-hydroxylase inhibitor
172. The effect of halofuginone, an inhibitor of collagen type I synthesis, on urethral stricture formation: In vivo and in vitro study in a rat model
173. Halofuginone, a specific inhibitor of collagen type I synthesis, prevents dimethylnitrosamine-induced liver cirrhosis
174. Liver cirrhosis is reverted by urokinase-type plasminogen activator gene therapy
175. Delivery of matrix metalloproteinase-1 attenuates established liver fibrosis in the rat
176. Albumin modified with mannose 6-phosphate: A potential carrier for selective delivery of antifibrotic drugs to rat and human hepatic stellate cells
177. Successful targeting to rat hepatic stellate cells using albumin modified with cyclic peptides that recognize the collagen type VI receptor